Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Farhat Nasim

Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Farhat Nasim

Articles By : Farhat Nasim

US: Sun Pharma allegedly dismisses employee for complaining about improper drug distribution, violation of FDA regulatons

Farhat Nasim19 July 2020 11:00 AM IST

New Delhi: In a major setback to Sun Pharmaceuticals Ltd., an erstwhile sale representative filed a retaliation lawsuit alleging that she was...

NPPA fixes retail price of 7 formulations; Details

Farhat Nasim18 July 2020 3:23 PM IST

New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India...

Healthcare focused SaaS startup Zealthix raises USD 1.1 million in seed round

HealthQuad raises Rs 514 crore for second fund

Farhat Nasim18 July 2020 9:45 AM IST

HealthQuad said the fundraise entrusts strong and positive belief in disruptive healthcare business models that will address the imminent and...

Gross Medical Negligence: Breach Candy Hospital, Doctor directed to pay Rs 7.5 lakh compensation

Farhat Nasim17 July 2020 7:25 PM IST

Mumbai: Setting aside an order passed by the Maharashtra State Consumer Forum, the National Consumer Disputes Redressal Commission (NCDRC) has...

CONTROVERSY: DCGI exempts Biocon from Phase 3 trial of COVID drug Itolizumab, ICMR sees red

Farhat Nasim17 July 2020 4:21 PM IST

Bengaluru: In a major controversy, the exemption of biotechnology major Biocon from conducting Phase 3 trials of its psoriasis drug...

DCGI approves India first fully indigenously developed vaccine against pneumonia

Farhat Nasim16 July 2020 1:00 PM IST

The ministry said the vaccine will be used for active immunization against invasive disease and pneumonia caused by ''Streptococcus pneumonia'' among...

Govt likely to issue unique QR Coding for all medicine packs

Farhat Nasim16 July 2020 12:31 PM IST

A various set of instructions regarding the tracing and tracking of medicines issued by different authoritative departments have created perplexity...

CDSCO allows import of drugs with residual shelf life less than 60 percent till Oct 31

Farhat Nasim15 July 2020 1:52 PM IST

New Delhi: Through a recent notification, the apex drug regulator, Central Drugs Standard Control Organisation (CDSCO) has extended the deadline...

Indian stent maker giant SMT to sell 30 percent stake for Rs 1100 crores

Farhat Nasim14 July 2020 5:54 PM IST

Part of the funds raised from the stake sale will be used for clinical trials in the US and for building a Rs 250 crore manufacturing plant in...

Do not conduct PG medical exam: SDPGA moves Dr MGR Medical University

Farhat Nasim14 July 2020 1:32 PM IST

Chennai: Considering the extraordinary situation for conducting Post-Graduate medical (PG medical) exams, the Government Service Doctors and...

Mumbai: Pharmacist, aide arrested for selling COVID drug Remdesivir for four times its price; hints at bigger nexus

Farhat Nasim13 July 2020 4:38 PM IST

The deal was closed for Rs 20000 per vial, stating that the drug was being sold in the black market from a medical store of a reputed hospital in the...

DoP junks Cipla plea against NPPA for price fixation of Synchrobreathe Inhaler

Farhat Nasim12 July 2020 3:00 PM IST

New Delhi: In a setback to drugmaker Cipla Ltd., the Department of Pharmaceuticals (DoP) has rejected its review petition filed against...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok